{"id":"W4365136161","doi":"10.1182/bloodadvances.2022009311","title":"Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Genentech; AOP Orphan; Italfarmaco; Angelini Pharma; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Jazz Pharmaceuticals; Gilead Sciences; MorphoSys; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; Constellation Pharmaceuticals","keywords":"Ruxolitinib; Discontinuation; Medicine; Anemia; Internal medicine; Randomized controlled trial; Myelofibrosis; Neutropenia; Adverse effect; Gastroenterology; Bone marrow; Chemotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02127661,0.001299856,0.004726354,0.00113154,0.0003882552,0.002383339,0.0008922019,0.001346005,0.002638805],"category_scores_gemma":[0.01941125,0.0004802201,0.01023511,0.002091402,0.0006452617,0.001417588,0.0007322787,0.002185267,0.0002153307],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001536276,"about_ca_system_score_gemma":0.002164251,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006247295,"about_ca_topic_score_gemma":0.001679572,"domain_scores_codex":[0.9898251,0.006806841,0.0009839272,0.0008529012,0.001087674,0.0004435814],"domain_scores_gemma":[0.9866455,0.006006869,0.004805591,0.0006922642,0.00107579,0.0007738867],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.6057711,0.001736956,0.01890053,0.02033321,0.2036144,0.0001451205,0.0001283101,0.002796142,0.002109265,0.0006465706,0.005094759,0.1387236],"study_design_scores_gemma":[0.6379011,0.04267995,0.07865324,0.003914305,0.2176057,0.0003949536,0.0001274496,0.004221199,0.001445288,0.002044423,0.01084863,0.000163726],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5213154,0.4380756,0.008573918,0.003744498,0.0008051547,0.0106893,0.01062324,0.000586251,0.00558666],"genre_scores_gemma":[0.9140409,0.06117761,0.006294308,0.003099219,0.0007583729,0.007294498,0.00634359,0.0001123745,0.0008792276],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02127661,"threshold_uncertainty_score":0.1125228,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02911296920830965,"score_gpt":0.359403814225357,"score_spread":0.3302908450170474,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}